Molecular Partners Ag (MOLN) Change in Receivables (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Change in Receivables of -$623.18 for Q1 2026, up 66.02% year-over-year from -$375.36 in Q1 2025, and down 100.1% quarter-over-quarter from $606548.3 in Q4 2025.
Molecular Partners Ag (MOLN) Change in Receivables (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Change in Receivables for 7 consecutive years, with -$623.18 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables rose 66.02% year-over-year to -$623.18; the TTM figure through Mar 2026 stood at $662395.3 (up 301.33% YoY), while the FY2025 annual figure was $606817.3, up 253.19% from the prior year.
- Change in Receivables retreated to -$623.18 in Q1 2026 per MOLN's latest filing, from $606548.3 in the prior quarter.
- Across five years, Change in Receivables topped out at $26.2 million in Q4 2022 and bottomed at -$24.4 million in Q3 2022.
- Historically, Change in Receivables has averaged $1.5 million across 5 years, with a median of -$766.54 in 2023.
- On a YoY basis, Change in Receivables climbed as much as 650.4% in 2022 and fell as far as 546.98% in 2022.
- Molecular Partners Ag's Change in Receivables stood at $26.2 million in 2022, then sank by 104.01% to -$1.1 million in 2023, then jumped by 62.46% to -$394569.3 in 2024, then soared by 253.72% to $606548.3 in 2025, then sank by 100.1% to -$623.18 in 2026.
- Business Quant data shows MOLN's Change in Receivables at -$623.18 in Q1 2026, $606548.3 in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | -623.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -623.18 |
| Mar 31, 2026 | -623.18 |
| Dec 31, 2025 | 606,548.35 |
| Dec 31, 2025 | 606,548.35 |
| Sep 30, 2025 | 1.61 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | -1.55 Mn |
| Jun 30, 2025 | -1.55 Mn |
| Mar 31, 2025 | -1,834.10 |
| Mar 31, 2025 | -1,834.10 |
| Dec 31, 2024 | -394,569.31 |
| Dec 31, 2024 | -394,569.31 |
| Sep 30, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | -1.54 Mn |
| Jun 30, 2024 | -1.54 Mn |
| Mar 31, 2024 | -1,364.51 |
| Mar 31, 2024 | -1,364.51 |
| Dec 31, 2023 | -1.05 Mn |
| Dec 31, 2023 | -1.05 Mn |